Tsuruha maintains strong market positioning in Japan's retail pharmacy sector with over 1,600 stores nationwide, leveraging its diversified product portfolio and supplementary healthcare services. The company's competitive advantage stems from its extensive store network, established distribution capabilities, and integrated healthcare service offerings including blood testing and at-home drug delivery.
Cyborg Score Rationale
Tsuruha demonstrates solid fundamentals as a market-leading drugstore operator with consistent revenue generation, attractive dividend yields (6.62%), and strategic expansion through acquisitions. However, valuation concerns and typical challenges facing the retail pharmacy sector temper the outlook slightly.
Top Insights
Operates over 1,600 stores across Japan, making it one of the largest drugstore chains in the region with significant scale advantages
Diversified revenue streams beyond pharmaceuticals including cosmetics, medical supplies, nursing care products, and general merchandise reduce dependency on single product category
Provides value-added healthcare services including blood testing, disease prevention solutions, and at-home drug delivery to enhance customer loyalty
Strong dividend yield of 6.62% reflects mature business model with stable cash generation and shareholder-friendly capital allocation
Named Competitors
Welcia Holdings — Major pharmacy chain operator competing in Japan's retail drugstore market
Kamenoko — Secondary drugstore brand operated under Tsuruha Holdings
Recent Developments
JPMorgan upgraded Tsuruha Holdings from Neutral to Overweight with raised price target (recent)
Morgan Stanley downgraded competitor Welcia Holdings from Overweight to Equalweight (recent)
Open the full interactive Tsuruha Holdings Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.